Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

19 results
Display

Prostate Cancer Mortality and Use of 5-Alpha Reductase Inhibitors

Foldes CA, Wang R, Canfield S

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia

Chung JS, Seo WI, Oh CK, Kim SC, Park MC, Park SH, Yu J, Lee CH, Kim W, Park TY, Min KS, Chung JI

PURPOSE: Preoperative use of 5α-reductase inhibitors (5ARIs) may cause fibrosis of the prostate tissue and reduce the efficiency of thulium laser surgery for treating benign prostate hyperplasia (BPH). Thus, we...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Persistent Erectile Dysfunction after Discontinuation of 5-Alpha Reductase Inhibitor Therapy in Rats Depending on the Duration of Treatment

Sung HH, Yu J, Kang SJ, Chae MR, So I, Park JK, Lee SW

PURPOSE: The current study is aimed to assess whether a longer duration of 5α-reductase inhibitor (5α-RI) exposure was associated with higher rate of permanent erectile dysfunction (ED) in a rat...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Course of the Benign Prostate Hyplasia Patients during the Intermittent Use of 5-Alpha Reductase Inhibitors

Choi K, Kim B, Cho IC, Min SK

PURPOSE: 5-Alpha reductase inhibitors (5ARI), inhibit the conversion of testosterone to dihydrotestosterone, which is essential in prostate hyperplasia, and decreases the prostate volume directly. On the other hand, 5ARI have...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Safety and Efficacy of the Coadministration of Sildenafil and Finasteride

Lee SW, Lee SH, Kim KS, Lee S, Chung JH

PURPOSE: The 5-alpha reductase inhibitors (5ARI) are one of the most commonly used medications for the treatment of benign prostatic hyperplasia (BPH). Phosphodiesterase type-5 inhibitors are also used to treat...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prostate-Specific Antigen Kinetics Following 5α-Reductase Inhibitor Treatment May Be a Useful Indicator for Repeat Prostate Biopsy

Heo JE, Koo KC, Hong SJ, Park SU, Chung BH, Lee KS

PURPOSE: To evaluate parameters for determining repeat prostate biopsy in patients with 5α-reductase inhibitor (5ARI) treatment after initial negative biopsy. MATERIALS AND METHODS: From January 2007 to December 2015, patients who...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Significance of intraprostatic architecture and regrowth velocity for considering discontinuation of dutasteride after combination therapy with an alpha blocker: A prospective, pilot study

Shindo T, Hashimoto , Shimizu T, Itoh N, Masumori N

PURPOSE: We conducted a prospective single-center study to evaluate the possibility of discontinuation of dutasteride after combination therapy with an alpha blocker for benign prostatic hyperplasia (BPH). MATERIALS AND METHODS: We...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparative analysis of benign prostatic hyperplasia management by urologists and nonurologists: A Korean nationwide health insurance database study

Park J, Lee YJ, Lee JW, Yoo TK, Chung JI, Yun SJ, Hong JH, Seo SI, Cho SY, Son H

PURPOSE: To compare the current management of benign prostatic hyperplasia (BPH) by urologists and nonurologists by use of Korean nationwide health insurance data. MATERIALS AND METHODS: We obtained patient data from...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia

Kim W, Jung JH, Kang TW, Song JM, Chung HC

PURPOSE: To assess changes in lower urinary tract symptoms (LUTS), prostate volume, and serum prostate-specific antigen (PSA) after discontinuation of 5-alpha reductase inhibitor (5ARI) combination therapy in patients with benign...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
alpha-Blocker Monotherapy and alpha-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results

Shin TJ, Kim CI, Park CH, Kim BH, Kwon YK

  • KMID: 2315386
  • Korean J Urol.
  • 2012 Apr;53(4):248-252.
PURPOSE: We compared the effects of alpha-adrenergic receptor blocker (alpha-blocker) monotherapy with those of combination therapy with alpha-blocker and 5-alpha-reductase inhibitor (5-ARI) on benign prostatic hyperplasia (BPH) progression for over...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-alpha Reductase Inhibitor

Choi H, Chang YS, Park BH, Ko DH, Moon YJ, Kim JB

PURPOSE: To compare the clinical therapeutic efficacy of finasteride and dutasteride as 5-alpha reductase inhibitor (5-ARI) in the medical treatment of benign prostate hyperplasia. MATERIALS AND METHODS: From July 2007 to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia

Cho KJ, Kang SH, Kim HS, Koh JS, Kim JC

  • KMID: 2232810
  • Int Neurourol J.
  • 2011 Sep;15(3):152-157.
PURPOSE: Many patients with benign prostatic hyperplasia (BPH) have storage symptoms. The aim of this study was to evaluate the effects of treatment with a 5-alpha reductase inhibitor (5ARI) on...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect of 5-alpha Reductase Inhibitors on the Efficacy of Photoselective Vaporization of the Prostate with 120 W GreenLight HPS Laser

Park HJ, Kim HW, Kim TN, Park NC

PURPOSE: To evaluate the effect of preoperative 5-alpha reductase inhibitor (ARI) administration on the operative results of photoselective vaporization of prostate with 120W GreenLight HPS laser. MATERIALS AND METHODS: Data were...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effects of 5-alpha Reductase Inhibitor on Contr action of Erectile Tissue and Secretion of Seminal Fluid in Male Rabbits: Preliminary Study

Lee SY, Ha MS, Nguyen HB, Lee JH, Lee JH, Myung SC, Kim SC

PURPOSE: Adverse sexual experiences such as erectile dysfunction (ED), loss of libido, and ejaculation disorders have been consistent side effects of 5-alpha reductase inhibitors (5ARI). The aim of this study...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride

Choi YH, Cho SY, Cho IR

  • KMID: 2314614
  • Korean J Urol.
  • 2010 Oct;51(10):704-708.
PURPOSE: To compare and analyze the therapeutic effects and changes in the prostate-specific antigen (PSA) level with treatment with finasteride or dutasteride for benign prostatic hyperplasia (BPH) for 1 year. MATERIALS...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Benign Prostatic Hyperplasia

Kim CS

Benign prostatic hyperplasia (BPH), a pathological terminology that means benign proliferation of prostatic tissue, is commonly used as a clinical terminology indicating low urinary tract symptoms (LUTS) resulting from prostate...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effectiveness of Loxoprofen Sodium on Nocturia in Patients with Benign Prostatic Hyperplasia

Chang HS, Kim BK, Sohn JC, Park CH, Kim CI

PURPOSE: The effectiveness of Loxoprofen sodium, a non-steroidal anti-inflammatory drug (NSAID), on the nocturia in patients with benign prostatic hyperplasia (BPH), not responding to anticholinergics or hypnotics, as well as...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Voiding Dysfunctions in Primary Care Practices

Lee KS

The availability of new urologic medications has made it possible to manage a variety of urologic disorders successfully in a primary care setting. As a result, primary care physicians(PCPs) need...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cut-off Point of Large Prostate Volume for the Patients with Benign Prostatic Hyperplasia

Cho JS, Kim CI, Seong DH, Kim HS, Kim YS, Kim SJ, Cho IR, Cheon SH, Lee DH, Yang WJ, Choi YD, Hong SJ, Ju YS, Song YS, Kim SI, Chung BH

  • KMID: 2293800
  • Korean J Urol.
  • 2005 Dec;46(12):1246-1250.
PURPOSE: Prostate volume (PV) is a key predictor of both the progression and response to medical therapy for the patients suffering with benign prostatic hyperplasia (BPH). 5 alpha reductase inhibitors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr